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ABSTRACT 
Introduction: Voltage-sensitive optical (VSO) sensors offer a minimally invasive method to 
study the time course of repolarization of the cardiac action potential (AP). This 
Comprehensive in vitro Proarrhythmia Assay (CiPA) cross-platform study investigates 
protocol design and measurement variability of VSO sensors for preclinical cardiac 
electrophysiology assays. 
Methods: Three commercial and one academic laboratory completed a limited study of the 
effects of 8 blinded compounds on the electrophysiology of 2 commercial lines of human 
induced pluripotent stem-cell derived cardiomyocytes (hSC-CMs). Acquisition technologies 
included CMOS camera and photometry; fluorescent voltage sensors included di-4-ANEPPS, 
FluoVolt and genetically encoded QuasAr2.  The experimental protocol was standardized 
with respect to cell lines, plating and maintenance media, blinded compounds, and action 
potential parameters measured. Serum-free media was used to study the action of drugs, but 
the exact composition and the protocols for cell preparation and drug additions varied among 
sites.  
Results: Baseline AP waveforms differed across platforms and between cell types. Despite 
these differences, the relative responses to four selective ion channel blockers (E-4031, 
nifedipine, mexiletine, and JNJ 303 blocking IKr, ICaL, INa, and IKs, respectively) were similar 
across all platforms and cell lines although the absolute changes differed. Similarly, four 
mixed ion channel blockers (flecainide, moxifloxacin, quinidine, and ranolazine) had 
comparable effects in all platforms. Differences in repolarisation time course and response to 
drugs could be attributed to cell type and experimental method differences such as 
composition of the assay media, stimulated versus spontaneous activity, and single versus 
cumulative compound addition.  
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Discussion: In conclusion, VSOs represent a powerful and appropriate method to assess the 
electrophysiological effects of drugs on iPSC-CMs for the evaluation of proarrhythmic risk. 
Protocol considerations and recommendations are provided toward standardizing conditions 
to reduce variability of baseline AP waveform characteristics and drug responses. 
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1. Introduction 
The Cardiac Safety Research Consortium (CSRC), the Health and Environmental 
Sciences Institute (HESI) and the US Food and Drug Administration (FDA) have proposed a 
new paradigm to assess the clinical potential for pro-arrhythmia risk.  The Comprehensive in 
vitro Proarrhythmia Assay (CiPA) initiative is a multi-discipline approach to assaying 
propensity to arrhythmias: one component consists of evaluating drug actions on multiple 
cardiac ion channel currents and using this data to reconstruct in silico the drug effect on 
adult cardiac electrophysiology and subsequently to attribute a proarrhythmic score. A second 
component is designed to confirm the predicted cellular electrophysiological effects of a drug 
by assay in an in vitro cardiac muscle preparation; the consortium suggests the use of human 
stem cell (hSC)-derived cardiomyocytes (hSC-CM) (Colatsky, et al., 2016; Fermini, et al., 
2016; Pierson, et al., 2013; Sager, Gintant, Turner, Pettit, & Stockbridge, 2014; Trepakova, 
Koerner, Pettit, Valentin, & Committee, 2009). A third component of CiPA investigates 
biomarkers from the clinical electrocardiogram (J-Tpeak, Tpeak-Tend intervals) (Vicente, 
Zusterzeel, Johannesen, Mason, et al., 2018; Vicente, Zusterzeel, Johannesen, Ochoa-
Jimenez, et al., 2018).   
The CiPA initiative follows decades of effort and investment across the pharmaceutical 
and biotechnology industries and in centers of academic research to develop data-driven in 
vitro screening practices to reduce the risk of proarrhythmic cardiotoxicity in pharmaceutical 
chemistry. These efforts aim to hold screening assays to appropriately high standards by 
founding decision-making criteria on well-validated clinically-referenced large data sets 
(Kramer, et al., 2013; Park, et al., 2018; Pfeiffer, Vega, McDonough, Price, & Whittaker, 
2016; Redfern, et al., 2003; Sirenko, et al., 2013). Early efforts to reduce proarrhythmic risk 
in drug candidates focused on the relationship between inhibition of the IKr current 
transmitted through the Kv11.1 (hERG) potassium channel and prolongation of the QT 
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interval representing cardiac repolarization in the electrocardiogram 
(ICH_Expert_Working_Group, 2005; Sanguinetti, Jiang, Curran, & Keating, 1995), which is 
associated with clinical risk of torsades de pointes (TdP) life-threatening arrhythmia. 
However, subsequent analyses have revealed shortcomings in the accuracy of both hERG-
inhibiting drug concentrations (IC50s) and nonhuman preclinical species to accurately predict 
clinically safe or proarrhythmic compounds at relevant multiples of clinical exposure 
(Gintant, 2011; Jost, et al., 2013; Park, et al., 2018; Wallis, 2010). The CiPA paradigm 
proposes to look beyond the hERG channel and animal study paradigm with a mechanistic 
emphasis to improve the accuracy of preclinical prediction of clinical proarrhythmic risk. 
hSC technology introduces a powerful in vitro platform for scientific discovery and 
preclinical evaluation. hSC-derived cells advantageously enable high throughout assessment, 
strong reproducibility, translation into clinical studies, and potential applications in 
personalized and precision medicine for many therapeutic areas. Utilization of hSC-derived 
cells is in agreement with the 3Rs (Replace, Reduce, Refine the need for animal studies) 
(Beken, Kasper, & van der Laan, 2016; Tornqvist, et al., 2014). The increasing availability of 
patient- and diverse donor-derived pools of stem cells opens the door to a clinical-trial-in-a-
dish paradigm (Fermini, Coyne, & Coyne, 2018; Sayed, Liu, & Wu, 2016; Shinozawa, et al., 
2017) .  
hSC-CMs have been shown to display cellular electrophysiological properties that are 
often similar to human primary cardiomyocytes, including ionic currents, channel gating 
properties, ventricular- like action potentials, and expected sensitivity to multiple drugs (Bett, 
et al., 2013; Honda, Kiyokawa, Tabo, & Inoue, 2011; Ma, et al., 2011; Peng, Lacerda, Kirsch, 
Brown, & Bruening-Wright, 2010). A variety of approaches have been utilized in hSC-CM 
based assays, including patch clamp, microlectrode arrays, optical indicators of voltage, 
mechanical movement, cellular impedance, Ca2+ transients and others (Ando, et al., 2017; 
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Asakura, et al., 2015; Blinova, et al., 2017; Gossmann, et al., 2016; Guo, et al., 2011; Guo, et 
al., 2013; Kitaguchi, et al., 2017; Leyton-Mange, et al., 2014; Lu, et al., 2017; Lu, et al., 
2015; Nunes, et al., 2013; Pfeiffer, et al., 2016; Pfeiffer, et al., 2017; Piccini, Rao, Seebohm, 
& Greber, 2015; Puppala, et al., 2013; Scott, et al., 2014; Sirenko, et al., 2013; Sun & Nunes, 
2016; Zeng, Roman, Lis, Lagrutta, & Sannajust, 2016). These studies have provided 
promising evidence that hSC-CMs are a relevant cell model to study drug-induced cardiac 
abnormalities, including arrhythmia and QT prolongation, and display good in vitro 
concordance to clinical findings.  
Among the diversity of detection methods, a number of optical assays have been 
developed to visualize cardiomyocyte electrophysiology with voltage (transmembrane 
potential; cardiomyocyte action potential (AP))-sensitive fluorescent dyes and to perform real 
time recordings of hSC-CMs (Blazeski, et al., 2018; Lu, et al., 2017; Lu, et al., 2015; Passini, 
et al., 2017; Pfeiffer, et al., 2016; Pfeiffer, et al., 2017; Shadrin, et al., 2017; Sirenko, et al., 
2013; Zeng, et al., 2016). In addition to chemical dyes, fluorescent proteins have been 
bioengineered to either report fluorescence in response to cellular electrophysiology 
(genetically encoded voltage indicator; GEVI, or genetically encoded calcium indicator; 
GECI), or to alter cellular electrophysiology in response to illumination (optogenetic 
stimulation) (Klimas, et al., 2016; Shinnawi, et al., 2015; Xu, Zou, & Cohen, 2017). 
Compared with more traditional methods like patch clamp and field potential recording, these 
optical platforms often have the advantage of higher throughput (e.g., versus patch clamp) 
and the possibility of simultaneous detection of multiple aspects of cardiomyocyte 
electrophysiology, including beat rate, action potential duration (APD), triangulation of 
repolarization, conduction velocity, etc.  
As methods for assaying cardiac electrophysiology in hSC-CMs become more 
commonplace and the scale of use expands from individual laboratories to a broader 
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pharmaceutical and regulatory context, it is important to understand the degree to which the 
diversity in methods across platforms, protocols, and laboratories may create inconsistencies 
in results. In order to compare results gained from different methods, especially for predictive 
values, it is critical to have either a standardized protocol in place, or a framework for data 
contextualization per method and across time. Factors which may influence results of cell-
based in vitro assays such as those using hSC-CMs include but are not limited to: cell line 
and production lot variance, adhesion matrix coating protocol (if applicable), cell plating 
density, culture duration, culture medium, dye selection, assay conditions, and data 
interpretation. (These factors would also contribute to discrepancies in any assay involving 
cell lines recombinantly expressing hERG or any other ion channel or receptor of interest).  
This is a report of a CiPA  hSC-CM action potential cross-platform study initiated by the 
CSRC, HESI and FDA to evaluate experimental protocols and assess the variability and 
discriminating power of fluorescence-based electrophysiological signals obtained from 
commercial hSC-CMs. The goal of the study was to provide exemplar proarrhythmia assay 
data with a diverse selection of optical methods for recording the cardiomyocyte action 
potential, utilizing the same, well characterized, reference compounds at the same 
concentrations, tested in hSC-CMs of identical production lots, as a first step toward cross-
site standardization of protocols or validation frameworks. Each site measured and reported 
the same action potential parameters (e.g. beat rate and specified action potential durations). 
The study measured the effects on the action potential (AP) of hSC-CMs using a limited 
number (8) of well-known drugs and limited replicates (n=3 replicate wells or 1 large size 
monolayer per condition) and four different optical systems designed for medium throughput. 
The study was administered by the CiPA Myocyte Subgroup and involved three commercial 
enterprises (Clyde Biosciences Ltd UK, Vala Sciences Inc USA, and Q-State Biosciences Inc 
USA) and one academic laboratory (Cardiac Bioelectric Systems Laboratory, Johns Hopkins 
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University, USA) using a variety of optical methods and voltage sensors. The results show 
that features of depolarization and repolarization including action potential shape could be 
resolved by all platforms involved in the study, and that experimental conditions and the form 
of optical measurement system are critical variables in defining a standardized cellular 
response. 
2. Material and Methods 
2.1. Cell plating and culture conditions 
As determined by the CiPA Working Group, the core sites involved in the study were 
provided with frozen cell material from matched batches of 2 commercial cell lines. All 
groups received cells from two manufacturers namely Cor.4U® cardiomyocytes (lot 
CB142CL_V_4M) (Ncardia, formerly Axiogenesis), Cologne, Germany) and iCellTM 
cardiomyocytes (catalogue number CMC-100-010-001; donor 01434; lot 1093711) (Cellular 
Dynamics International, WI, USA). The culture conditions used by each group for Cor.4U 
and iCell cells are given below. 
Clyde Biosciences: Cor.4U and iCell cardiomyocytes were kept in liquid nitrogen until 
culture according to the instructions provided by the respective manufacturers. In both cases, 
the cells were cultured in 96-well glass-bottomed plates (MatTek, Ashland, MA, USA; Cat. 
No. P96G-1.5-5-F) coated with fibronectin (70µl/well at 10µg/ml in PBS [+Ca2+ & Mg2+]) 
(Sigma-Aldrich, St. Louis, MO, USA; Cat. No. F-1141) in an incubator at 37°C for 3h. The 
cell density for Cor.4U and iCell cardiomycytes were 0.78×105/cm2 (25,000 cells/well after 
adjustment by the manufacturer’s lot plating efficiency), the subsequent maintenance 
protocols followed manufacturer’s instructions and the corresponding maintenance media 
(Cor.4U: Cor.4U®-maintenance media; iCell: iCellTM-maintenance media). Experiments were 
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performed between days 4-8 (Cor.4U) and 10-15 days (iCell) post-thaw as recommended by 
the manufacturers, using media reported in Table 1 and Supplemental Table 1.  
Johns Hopkins University: Cor.4U and iCell cardiomyocytes were seeded onto 35mm 
plastic tissue culture dishes (#353001, BD Biosciences) as confluent monolayers for optical 
mapping. To match the size of the monolayer to the optical mapping field of view, the growth 
area of the 35mm dishes was restricted to a 10mm diameter circle by filling the 35mm dishes 
with a polydimethylsiloxane (PDMS) stencil, in which a 10mm diameter circular hole was 
punched out at the center, exposing the tissue culture-treated surface for monolayer culture. 
The 35mm dishes were then UV-sterilized and coated with Geltrex (#A1413302, 
Thermofisher, at 1:100 dilution) overnight before use. Cor.4U and iCells were prepared 
according to the manufacturers’ specifications. For Cor.4U cardiomyocytes, cells were 
thawed in manufacturer-provided medium according to manufacturer instructions and 
maintained for two days to allow recovery from cryopreservation. These cells were then 
dissociated, counted and plated at 1.60×105/cm2 (127,000 cells/well) to form confluent 
monolayers (which were not formed at the lower manufacturer’s recommended density). The 
monolayers were cultured in manufacturer-provided medium for an additional 8 days prior to 
optical mapping. For iCell cardiomyocytes, cells were thawed, counted and plated at 
2.55×105/cm2 (200,000 cells/well) to form confluent monolayers. The monolayers were 
cultured in manufacturer-provided medium for 10 days prior to optical mapping. Two g/ml 
ciprofloxacin was added to the media throughout culture of the Cor.4U cardiomyocytes, and 
25 g/ml gentamycin was added throughout culture of the iCell cardiomyocytes per 
manufacturer recommendations. 
Q-State Biosciences: Cor.4U and iCell cardiomyocytes were cultured in six-well plates 
(VWR, Radnor, PA, USA; Cat. No. 353046) coated with 0.1% gelatin (Millipore, Taunton, 
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MA, USA; Cat. No. ES-006-B) following manufacturer’s instructions. The cells were 
transduced to express the components of the optogenetic-GEVI construct Optopatch, which 
consists of CheRiff, a blue-light activated channelrhodopsin actuator, and QuasAr, a red light 
voltage reporter (Hochbaum, et al., 2014). Three (for Cor.4U) to five (for iCell) days after 
plating, hSC-derived CMs in each well were transduced overnight with custom made 
lentivirus for expression of CaViar (fusion construct of GEVI QuasAr2 and GECI GCaMP6f) 
or CheRiff (optogenetic channel). Virus was removed from the cells and maintenance 
medium added to each well. At 6 days post-thaw, to enable the option of simultaneous 
voltage and Ca2+ imaging with optical pacing using Optopatch, the CheRiff-expressing cells 
and CaViar-expressing cells were dissociated and re-plated into the same dish. CheRiff-
expressing cells were replated in the periphery and CaViar cells were replated in the center of 
each dish, as described previously (Dempsey, et al., 2016). Briefly, one side of a PDMS disc 
was treated with 10µg/mL fibronectin (Sigma-Aldrich, St. Louis, MO, USA; Cat. No. F2006) 
in 0.1% gelatin for 10 min at room temperature, dried and then pressed offset to one side onto 
a MatTek dish (Ashland, MA, USA; Cat. No. P35G-1.5-10-C). The remaining area was 
coated with 10µg/mL fibronectin in 0.1% gelatin overnight. CheRiff-expressing cells were 
trypsinized according to the manufacturer’s instructions and ~10,000 cells added to the 
exposed glass surface for 40 minutes at 37 °C in 5% CO2. Discs were removed, and the dish 
was washed with 150µL of maintenance medium. CaViar-expressing cells were trypsinized 
according to manufacturer’s instructions then re-plated overnight to a final density of 0.7 × 
105 cells/cm2 (45,000 additional cells/well). Maintenance medium (1.0 mL) was added to 
each dish, and media changes were conducted according to the manufacturer’s instructions. 
Cells were imaged 7-10 days (Cor.4U) and 14-17 days (iCell) post-thaw as recommended by 
the manufacturers.  
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Vala Sciences: Cor.4U and iCell cardiomyocytes were thawed and cultured in accordance 
with protocols suggested by the cell manufacturer, in 96 well plates featuring optically clear 
well bottoms (Cat. No., 655090, Greiner, Monroe, NC, USA). Cor.4U cardiomyocytes were 
plated at 1.40×105/cm2 (45,000 cells/well) on culture surfaces coated with fibronectin 
(10µg/mL, Cat. No. F1141, Sigma-Aldrich, St. Louis, MO, USA), in plating media including 
0.5 mg/mL puromycin, both provided by the cell manufacturer, and maintained at 37°C and 
5% CO2. The media was changed to the manufacturer’s maintenance media three hours after 
plating, replaced after 24 hours and every subsequent two days until assay of the Cor.4U 
cardiomyocytes after six days of culture. iCell cardiomyocytes were plated at 0.78×105/cm2 
(25,000 cells/well), calculated after applying the manufacturer’s plating efficiency (0.55) for 
the lot, on surfaces coated with 250µg/ml Matrigel (Corning 356237, Fisher Scientific, 
Waltham, MA, USA). The cells were maintained for the first two days in plating medium 
provided by the manufacturer at 37°C and 7% CO2. The media was replaced with 
maintenance media provided by the manufacturer supplemented with 25µg/ml gentamicin 
(Gibco, Waltham, Massachusetts, USA) every two days, and with antibiotic- free media 24h 
before assay. iCell cardiomyocytes were maintained in culture for 10 days prior to Kinetic 
Imaging Cytometry (KIC) assay. Both lines of cardiomyocytes displayed spontaneous 
beating within 48h of thawing and maintained this phenotype throughout the duration of the 
experiment. 
2.2. Optical recordings and compound testing 
Clyde Biosciences: On the day of experiments cells were washed in serum free media the 
composition of which differed for the two cell types: Cor.4U cardiomyocytes were exposed 
to BMCC media (Bohlen Modified Complete Culture, NCardia Ax-M-BMCC250); iCell 
cardiomyocytes to DMEM (Dulbecco's Modified Eagle Medium, Gibco 11966) 
supplemented with 10mM galactose and 10mM sodium pyruvate as per manufacturers’ 
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instructions (Supplemental Table 1). hSC-CMs were loaded with 6μM di-4-ANEPPS 
(Biotium; Cat. No. 61010) in serum-free media (SF media) for one minute at room 
temp.  Cells were then washed in indicator- free cell specific SF media and stored in an 
incubator for 2h prior before experimentation.  The multi-well plate was placed on a stage 
incubator (37°C, 5% CO2, water-saturated air atmosphere OkoLabs Inc, USA) of the 
CellOPTIQ platform (Clyde Biosciences Ltd, Glasgow, Scotland).  The di-4-ANEPPS signal 
was recorded by a PMT from an area 0.2 x 0.2 mm using a 40x (NA 0.6) objective 
lens.  Baseline spontaneous activity was recorded by capturing a 15-20s segment of 
fluorescent signal and this was repeated 30min after exposure to the drug or vehicle (DMSO). 
Drugs were tested at four concentrations (N=3 for each concentration) with matched vehicle 
controls (0.1% DMSO) for each concentration, added at 5X concentration by removing 20% 
volume and replacing with drug.  Fluorescence signals were digitized at 10 kHz.  Offline 
analysis was performed using proprietary software (CellOPTIQ).   
Johns Hopkins University: On the day of drug testing, cultures were transferred to 
Tyrode’s solution (Supplemental Table 1). Monolayers were stained in Tyrode’s solution 
containing 10μM voltage sensitive dye di-4-ANEPPS (D1199, Invitrogen, Grand Island, NY) 
for 10min. The PDMS cell culture stencil was removed from the 35mm culture dish after 
brief rinse of the monolayer, and then 2mL of Tyrode’s solution was added to the culture dish 
prior to test compound treatment and optical mapping. For Cor.4U monolayers, 10μM of 
blebbistatin (B0560, Sigma-Aldrich, St. Louis, MO) was also applied to inhibit motion. 
Experiment temperature was controlled at 37°C by using a heated stage throughout the 
recordings. Electrical stimulation was applied through a pair of platinum electrodes placed at 
the edge of the monolayer. Optical action potentials were recorded using a MiCAM Ultima-L 
CMOS camera (SciMedia, Costa Mesa, CA) with tandem 1x Plan Apo lens (Leica, with 0.44 
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NA). The field of view was 1 x 1 cm and had 100 x 100 pixel spatial resolution at 500 
frames/sec. Each pixel represented an area of approximately 0.1mm x 0.1mm. 
Stock solutions of all compounds were prepared in DMSO (vehicle) according to 
protocols provided for CiPA studies, which is at 1000x the highest testing concentration. The 
stock solution was diluted in Tyrode’s solution at 1:100 for optical mapping. For DMSO 
control, 1:100 DMSO was prepared in Tyrode’s solution. The final concentration of DMSO 
was <0.1% at all times. Untreated baseline, then 4 test compound concentrations were 
recorded for each test article (test compound, or vehicle control) sequentially. Ten minutes 
were allowed between each compound concentration for the compound to reach steady-state 
effects before recording optical action potentials. Optical action potentials were analyzed 
using custom MATLAB programs. The region of monolayer analysed was automatically 
determined based on signal-to-noise ratio of action potentials recorded from individual sites, 
and approximately 7000 measurements were made per monolayer. A sliding 5 × 5 pixel 
Gaussian filter was applied spatially to improve signal quality across the field of view. 
Because of the large number of cells required per monolayer and extensive manual aspects of 
the experimentation, technical replicates were performed only at baseline; otherwise it was 
one monolayer per test condition. Action potential parameters as described in Data Analysis 
were calculated using MATLAB routines. 
Q-State Biosciences: Prior to imaging, medium was removed from the dish and 1.5 mL of 
warmed maintenance medium without phenol red, vitamins and amino acids was added 
(Supplemental Table 1). Cells were kept at 37°C in 5% CO2 for 30 minutes prior to 
imaging. Imaging was performed on a microscope custom-built to actuate and record 
Optopatch. Cells were maintained at 37 °C with a heated stage (Warner Instruments) and 
objective collar (Bioptechs), and 100% humidity at 5% CO2. The imaging protocol comprised 
the following: spontaneous activity (30s), followed by activity at 1 Hz and 2 Hz pacing (15s 
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each), repeated in two different fields of view within each dish. Drug addition within each 
dish included a vehicle (DMSO) control, followed by cumulative ascending concentration 
(four test concentrations, three replicate dishes per concentration, 10 minute treatment time 
per concentration) by removing 10% of the dish volume and adding the drug at 10X the final 
concentration. Pulses of blue LED illumination (6 ms, 0.5 W/cm2, λ = 488 nm) were used to 
pace the CMs by stimulating CheRiff in the peripheral cells. Blue laser light (λ = 488 nm, 
0.15 W/cm2) and red laser light (λ = 640 nm, 50 W/cm2) excited fluorescence of GCaMP6f 
and QuasAr2, respectively, in the central cells (QuasAr2 providing transmembrane voltage 
data, the subject of this study). Fluorescence was collected with a 20x water immersion 
objective (NA1.0). An illumination area of ~200 m x 200 m was used to image 
cardiomyocytes and generate the traces used to compute action potential statistics. A dual-
view system projected emission from GCaMP6f and QuasAr2 onto adjacent halves of a 
sCMOS camera (Orca Flash 4.0, Hamamatsu), operating at a frame rate of 500 Hz. The 
signals from the 500x500 pixels of the camera were averaged together to obtain the AP and 
its parameters, and 3 areas were measured and averaged per well. Voltage and calcium traces 
were scaled to fractional changes in fluorescence relative to baseline (ΔF/F). In the current 
study, only voltage data from spontaneously active and 1Hz stimulation was used to compare 
with the 3 other platforms. 
Vala Sciences: Cardiomyocytes were loaded with FluoVolt and PowerLoad (Invitrogen, 
Cat. No. F10488, Carlsbad, CA, USA) per manufacturer instructions, in a loading buffer of 
20mM HEPES in HBSS and 200ng/mL Hoechst 33342. Cells were loaded for 30 minutes at 
37°C. Stock solutions of each blinded compound test concentration were prepared in DMSO 
at 1000-fold the test concentration, aliquoted and stored at -80°C. High content analysis was 
conducted using an IC-200 Kinetic Image Cytometer (KIC; Vala Sciences, San Diego, CA). 
Compounds were diluted to final concentration in Tyrode’s solution (Supplemental Table 
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1). Following dye loading, the cells were washed with 37°C Tyrode’s solution. The 
compounds or vehicle (DMSO) control, diluted to their final test concentrations in 37°C 
Tyrode’s solution, were then 100% exchanged with solutions in the appropriate wells. 
Compound treatments were performed in triplicate wells and compared against 6 replicate in-
plate vehicle control wells. For the experiment with Cor.4U cardiomyocytes, a total of 33 
replicates of vehicle control were used, and for the experiment with iCell cardiomyocytes, a 
total of 36 replicates of vehicle control were used.  A final DMSO concentration of <0.1% 
was maintained in each well assessed in the study.  The cardiomyocytes were incubated with 
test compounds at 37°C for 20 minutes prior to being imaged. A KIC was used to capture 
movies of the action potentials, described previously (Cerignoli, et al., 2012; Lu, et al., 2015). 
The environmental control chamber of the KIC was set to 37°C. For these experiments the 
KIC was fitted with a 20x NA 0.75 objective and captured one image of the nuclei (Hoechst), 
then recorded 20 sec of action potential activity (FluoVolt) at 30 frames/sec from each well. 
An area of 0.58 x 0.58 mm2 of cells was recorded for each well. Action potential analysis was 
performed using CyteSeer automated image analysis software (Vala Sciences Inc., San 
Diego, CA, USA). Briefly, the FluoVolt intensity of around 1785 x 1785 pixels within a field 
of view of 0.58 x 0.58 mm2 was averaged to obtain an AP trace that was used to determine 
the reported per well values. 
A summary of the optical platforms, and the VSO sensor, type of pacing, plating density, 
media, detector and acquisition rate for all four test sites is given in Table 1. The drugs used 
and their concentration and ion channel targets are shown in Table 2. 
2.3. Drug list and stock preparation 
The CiPA Myocyte Subgroup selected eight compounds for the cross-platform study 
(Table 2). Compounds were distributed blinded by National Cancer Institute (U.S. 
Department of Health and Human Services) to all participating sites with instructions for 
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preparation in DMSO (also provided from a common stock) and instructions on the four 
dilutions to be used in the study. The compound set included four ion channel-selective 
compounds to test inhibition of INa (mexiletine), ICaL (nifedipine), IKr (E-4031), and IKs (JNJ 
303), and four mixed ion current blocking agents flecainide, moxifloxacin, quinidine, and 
ranolazine. Although mexiletine has hERG inhibitory properties (Supplemental Table 4), it 
was not classified as inducing TdP risk by the CiPA Myocyte Subgroup on the basis of its 
categorization in the QTDrugs Lists at CredibleMeds® (known risk of TdP or other 
categories, https://crediblemeds.org) (Supplemental Table 3).  
2.4. Data Analysis 
The average AP waveform was generated based on a minimum of 15 sec continuous 
record of spontaneous and/or stimulated APs. The following parameters were measured: 
action potential rise time (Trise) i.e. time from 10% to 90% of the upstroke; action potential 
duration (APD) at 3 points on the repolarisation phase (30%: APD30, 60%: APD60 and 90%: 
APD90); a triangulation index (APD90-APD30; Triang) or normalized triangulation index 
(Triang/APD90); and average cycle length (CL) or beat rate (BR) were also recorded.   
Unusual AP configurations which suggested altered excitability or predisposition to 
arrhythmia- like events were observed on addition of some drugs. These events were recorded 
according to a category of event based on waveform shape as shown in Supplemental 
Figure 1. This shows different examples of arrhythmia- like AP waveforms and quiescence.  
2.5. Statistics 
Statistical analysis was performed using ANOVA followed by Dunnett's test following 
ANOVA to allow the comparison of a number of treatments with a single control.  Statistical 
significance was designated as * P<0.05, **P<0.01, *** P<0.001, ****P<0.0001. 
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3. Results 
3.1. Baseline values 
Examples of optical recordings measured at each of the four test sites are shown in 
Figure 1 for Cor.4U and iCell cardiomyocytes. The average (mean), standard deviation (SD), 
and coefficient of variation (CoV) for the AP waveform parameters for both cell types 
recorded on the 4 platforms without test compound treatment is given in Table 3. At three 
sites (Clyde, Q-State and Vala), spontaneously beating cells were recorded. One of the sites 
(Q-State) also recorded with electrical stimulation to control beat rate (1 Hz), and at the 
fourth site (JHU), only stimulated (1 Hz) recordings were made. CoV of cycle length values 
recorded from spontaneously active cells (0.11-0.65) may be used as a measure of the 
regularity of the spontaneous beating. APD90 CoV was less than 0.25 for all methods and cell 
types. There were marked differences in both depolarization and repolarization characteristics 
across sites and cell types. The smallest differences appeared within cell type and between 
sites using comparable media composition, e.g. Q-State and Clyde used similar media 
compositions for iCell recordings and the range of CL and APD values was comparable in 
both groups. The Tyrode’s solution used at the Vala and JHU sites had similar composition. 
At the Vala site, which did not utilize beat rate control, cycle length and APD90 for iCell 
tended to be longer and less variable than at the other sites (Clyde and Q-State) with 
spontaneous recording, whereas at the JHU site, which controlled beat rate with 1 Hz 
stimulation, iCell APD90 was more similar to the sites with shorter cycle length (Clyde and 
Q-State). For Cor.4U, spontaneously beating cells at the Q-State site tended to have longer 
cycle lengths than at the Clyde and Vala sites. Shorter cycle lengths coincided with fewer 
post-thaw days of culture for Cor.4U (range 4-10 days), but not for iCell (range 10-17 days). 
A limitation of beat rate control is that it can be performed only at rates greater than the 
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spontaneous beat rate (overdrive pacing), which may be altered by drug-induced 
electrophysiological changes. 
Figure 2 shows the relationship between the cycle length obtained from spontaneously 
active and 1Hz stimulated cells and the associated APD90. Panel A shows the data from all 4 
sites for Cor.4U cardiomyocytes, and panel B the data for iCell cardiomyocytes. The cycle 
length vs. APD90 relationship for the combined dataset from all four sites was roughly co-
linear for iCell cardiomyocytes, which suggests an underlying linear relationship unaffected 
by variations in experimental conditions at the four sites. In contrast, the overall Cor.4U cycle 
length vs. APD90 relationship was not linear, across or within sites. Cor.4U cells were 
recorded in the same media as iCell recordings at all except the Clyde site. Table 4 lists the 
regression equation for the combined dataset, and the regressions for the spontaneously 
beating datasets of individual sites are listed in Supplemental Table 2. For iCell cells, the 
slope for all 3 groups was approximately 0.1. The slope for Cor.4U cells for both Clyde and 
Vala was approximately 0.1, but Q-State data did not fit this relationship. 
Rise time values ranged widely and appeared broadly inversely correlated with 
acquisition rate (Table 3), with TRise ranging from approx. 6ms (iCell Clyde site) to approx. 
40ms (iCell Vala site). The response time constant of a VSO can potentially limit the 
temporal resolution of data collected in optical assays. However, the VSOs utilized in this 
study have relatively fast kinetics (Table 1) which should not be limiting to the features 
measured in this study: (< 1 ms) di-4-ANEPPS (Loew, et al., 1992), (< 1 ms) FluoVolt 
(VoltageFluor2.1) (Miller, et al., 2012), (< 3 ms) QuasAr2 (Hochbaum, et al., 2014). Rise 
time may also be proportional to the size of the area of sampled cells, because of the time 
delay for the depolarization wave to propagate across the measurement area, but this was not 
found to be the case. Q-State, which had the smallest sampling area of 0.4m x 0.4m (Table 
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1), had longer Trise than Clyde, which had a much larger sampling area of 0.2mm x 0.2mm 
but the shortest rise times and highest acquisition rate. On the other hand, within cell type, 
spontaneously beating hSC-CM TRise bore a positive relationship to cycle length that was 
linear for iCell cells, and a broad positive correlation to the concentration of NaCl (range 86 
mM – 135 mM) and total sodium ion (range 110 mM – 175 mM) in the extracellular imaging 
solution (Supplemental Table 1). 
3.2. The effect of vehicle on electrophysiological parameters 
Figure 3A shows an example of the effect of DMSO vehicle on the voltage signals from 
hSC-CMs.  An example of the average effects of the vehicle on a range of parameters (cycle 
length, APD90, triangulation and rise time) from a single site (Clyde) is shown in Figure 3B. 
CL and APD90 showed no effect with minimal variation, while triangulation and TRise were 
more variable.  The mean values showed no difference from zero, and this was consistent for 
both cell types used in the study. As shown in Figure 3C for the values of APD90, DMSO 
had similarly minimal effects on average AP characteristics across all the sites. One site 
(Vala) did not make baseline measurements in the absence of vehicle. 
3.3. Example of the electrophysiological response to 4 selective ion channel blockers  
An example of the change in AP parameters caused by the four selective ion channel 
drugs (E-4031, nifedipine, mexiletine, and JNJ 303) is shown for one site (Clyde) in Figure 
4. Panel A shows example traces before and 30 minutes after addition of a single 
concentration of the drug. E-4031 prolonged the action potential in both cell types with 
marked increases in triangulation indicating prolongation of the late repolarisation phase. 
Nifedipine shortened both cycle length and APD90 while mexiletine caused significant 
changes in APD and tended to increase cycle length. Trise was also altered by compound 
treatment, albeit in a more variable and frequently bidirectional manner. The IKs blocker JNJ 
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303 showed no significant effects in Cor.4U cardiomyocytes but reduced cycle length in iCell 
cardiomyocytes with few other significant effects on the waveform shape.  
3.4. Summary of effects of all 8 CiPA compounds on the AP waveform across all sites 
All eight (blinded) compounds (Table 2) were applied at each site to iCell and Cor.4U 
cells. These were applied at two sites (Clyde and Vala) at a single concentration per well, and 
at the other two sites (JHU and Q-State) using cumulative concentrations in the same wells. 
For brevity and illustration, Figure 5 compares the results for the 8 tested compounds (Table 
2) across all sites for the key repolarization parameter (APD90). The results for all other 
measured parameters (spontaneous cycle length, APD30, APD60, rise time, triangulation, 
normalized triangulation) can be found in Supplemental Figure 2. Depending on the test 
site, action potential recordings were obtained during spontaneous activity and/or electrical or 
optical pacing. Generally, the potent hERG inhibitors E-4031, flecainide, and quinidine 
(Supplemental Tables 3 & 4) prolonged the action potential recorded from both Cor.4U and 
iCell cardiomyocytes in a concentration-dependent manner, and/or caused arrhythmias or 
stopped beating, consistent with the blockade of repolarizing IKr. Nifedipine caused a 
concentration-dependent reduction in APD90, consistent with inhibition of ICaL. JNJ 303 
caused little to no alteration in APD90. For compounds with mixed ion channel inhibition, 
some differences in sensitivity to sodium and calcium channel inhibition are apparent, with 
some preparations (per cell type and experimental protocol) more reflective of a hERG 
inhibitory effect, and others more sensitive to an inward current inhibition (e.g. quinidine 3-
10 µM). Differences in experimental protocol (e.g. cell density or compound exposure 
duration) may influence these differences in sensitivity. However, despite the differences in 
cell type, media composition and spontaneous/stimulated beat rate as well as cumulative vs. 
individual dosing protocols, there was broadly consistent drug effect across sites. 
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3.5. Incidence of arrhythmia-like events 
Arrhythmia-like events were documented per the agreed key (Supplemental Figure 1). 
The reported incidence and class of events are shown in Table 5. The low number of drugs, 
sites, and cell lines tested in this cross-platform study makes statistical comparisons of 
limited value, but consistent trends were clear. A comparison of the channel inhibition IC50s 
of each compound, as well as their clinical exposure are listed in Supplemental Tables 3 & 
4. The compound concentration ranges that induced arrhythmia- like events in this study are 
also listed. Generally there was some consistency across sites: all sites reported events using 
the hERG blocking drugs E-4031 and quinidine, which are known to cause QT prolongation 
and high TdP risk. No site observed arrhythmia- like events with JNJ 303 and moxifloxacin. 
Nifedipine caused quiescence or a tachyarrhythmia (high frequency activity typically lacking 
normal action potential morphology) at 3 out of 4 sites in the concentration range that was 
about 2-fold above the IC50 of Cav1.2, and at least 3-fold higher than the therapeutic 
exposure. Because Cav1.2 is strongly inhibited at these concentrations, APD decreases, 
permitting rapid reactivation due to high frequency focal activity or re-entrant activity. 
Ranolazine cause arrhythmia- like events at only one site, at concentrations relevant to hERG 
inhibition and at the top of the QTc-prolonging clinical exposure range. Flecainide and 
mexiletine were associated with arrhythmia- like events in 3 out of 4 sites, flecainide at near 
the clinically QTc-prolonging concentration, and mexiletine at 10- to 20-fold above the 
therapeutic exposure.  Overall, the test concentrations at which the drugs caused arrhythmia-
like events were comparable with the ion channel IC50s (within 3-fold), and for the 7 drugs 
tested clinically, test concentrations producing arrhythmia-like events were in agreement with 
QTc measurements and documented arrhythmia at that exposure. These observations 
demonstrated that with protocol optimization, VSO platforms can be a useful tool for 
assessing drug-induced arrhythmia in clinically relevant concentration ranges. 
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4. Discussion 
The goal of this cross-platform study was to assess the variability among four different 
sites using various VSO techniques to measure action potential changes in response to a panel 
of eight drugs with well-known electrophysiological effects. Efforts were made to standardize 
the test conditions by using identical batches of the same commercial cell lines, 
manufacturer-provided plating and maintenance media, and drug stocks prepared and 
deidentified by a third party. At all sites, drugs were tested in serum-free media to avoid 
uncertainty due to drug binding to protein in the media. Because of the small number of sites, 
statistical tests of differences were not feasible. Nevertheless, with a few exceptions, the drug 
responses were quite similar (Figure 5), despite differences in voltage sensors, optical 
measurement systems, and experimental conditions (plating density, imaging solution, pacing 
conditions, method of compound addition) as summarized in Table 1. Furthermore, despite 
noted differences in some electrophysiologic characteristics of hSC-CMs vs. acutely isolated 
native human ventricular myocytes, these studies demonstrate the ability to detect delayed 
and altered cellular repolarization, as has been demonstrated previously (Casini, Verkerk, & 
Remme, 2017; Jonsson, et al., 2012).  
Some observations can be gleaned from the experimental data of the four sites. In general, 
APDs were longer for iCell than for Cor.4U cardiomyocytes (Figure 1, Table 3). For cells 
that were spontaneously beating, APD30 and APD90 were longer for Vala (iCell only), and for 
cells that were paced they were longer for JHU (Table 3). These two sites assayed drug 
effects in Tyrode’s solutions, which are commonplace in electrophysiological research, while 
the other two sites used serum-free medias (Table 1, Supplemental Table 1) with unique 
ionic and biochemical composition which may influence baseline cardiomyocyte 
electrophysiological characteristics. When plotted against the cycle length of the spontaneous 
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beat rate, the differing APD90 exhibited a common linear relationship (Figure 2) for iCell 
cardiomyocytes (approx. 0.1 ms APD90 per ms cycle length), but not for Cor.4U 
cardiomyocytes, although for two out of three of the spontaneously beating sites, the intra-
site regression also had a slope of ~ 0.1. 
The effects of the eight test compounds on APD90 were similar in both cell lines, in at 
least three and sometimes in all four of the test sites (Figure 5). Effect sizes tended to be 
suppressed when beat rate was controlled (1Hz), versus in spontaneously beating 
cardiomyocytes. With increasing doses, little or no change in APD90 was observed with JNJ 
303. APD90 decreased with nifedipine (~ 30-50%). For compounds which have been 
observed to inhibit hERG (Supplemental Table 4), APD90 increased with a range of effect 
size relevant to TdP risk classification: smaller effects with mexiletine (typically < 50%; at 
highest test concentration, >50% in iCell at 2 sites and Cor.4U at 1 site, or stopped beating in 
iCell at 2 sites), ranolazine (~ 50-150%), and moxifloxacin (Cor.4U tended >50%), compared 
with a larger effect for E-4031, quinidine, and flecainide (in spontaneously beating cells, 
typically >100% and/or instances of stopped beating and arrhythmia). In compounds which 
inhibit multiple ion channels, for example quinidine, which has potency against hERG 
relevant to the lower concentrations tested here and potency against Nav1.5 and Cav1.2 near 
or above the higher concentrations tested here, relative sensitivity to inhibition of repolarizing 
or depolarizing currents may be influenced by experimental protocol. Overall, despite the 
systematically longer action potentials observed in iCell compared with Cor.4U cells, the 
changes in action potential parameters of both cell lines to test compounds were generally 
similar with regard to percent change (Figure 5 and Supplemental Figure 2). 
The incidence of these arrhythmia-like events as defined in Supplemental Figure 1 
(Table 5) was lowest for JHU, as the only site which used 1 Hz pacing and large (cm) sized 
cell monolayers, and lower at Q-State in paced versus spontaneously beating iCell. E-4031 
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and quinidine elicited events across all four sites in at least one cell line. Excluding JHU, 
these events also tended to be more frequent across sites for iCell compared with Cor.4U 
cardiomyocytes. The tendency of compound addition to stop cardiomyocyte spontaneous 
beating was increased in relation to the concentration at which compounds in an intermediate 
stock solution were added to the cells (i.e. 5X, 10X), versus full media exchange at 
compound dosing (1X). Cumulative dosing, and post-thaw handling (trypsinization & re-
plating, viral infection for transgene expression) may additionally contribute to this effect.  
Action potential measurements are traditionally obtained from cardiac tissues or 
individual cells using glass microelectrodes (e.g. whole cell clamp using glass micropipettes). 
However, this approach is extremely labor-intensive and is very low throughput, while the 
demands of a screening assay require at least medium throughput to efficiently assay drugs at 
the scale of commercial drug discovery and risk evaluation. To improve the throughput, 
automated patch clamp can be employed as a proven high throughput assay (Rajamohan, et 
al., 2016; Scheel, et al., 2014). However, measurements of action potentials and APD are 
highly sensitive to the quality of the seals that can be obtained with the cells, and artifacts can 
also be introduced via dialysis of solutions into the cell. 
At present, the primary methods for evaluating drug effects on the action potential of 
hSC-CMs are with field potential and fluorescent action potential recordings. Many 
investigators and organizations use extracellular multielectrode arrays (MEAs) to measure 
both the hSC-CM beat rate and the field potential duration. Under ideal recording conditions, 
the field potential is described as a second order filtered version of the action potential 
(Tertoolen, Braam, van Meer, Passier, & Mummery, 2018). In this description, field potential 
spike corresponds to the action potential upstroke, and field potential duration (measured as 
time from positive peak of spike to positive peak of repolarization wave) is theoretically 
linearly related to APD90 (Tertoolen, et al., 2018). However, it is the time course of 
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repolarisation of the action potential that is indicative of the pro-arrhythmic potential of a 
compound (Hondeghem, 2008; Hondeghem, Carlsson, & Duker, 2001). Action potential 
measurements provide more detailed information than is available from field potential 
reordings, such as AP rise time (a measure of fast sodium channel activity), AP duration at 
different levels of repolarization (APD30, APD60, APD90) and triangulation (duration of late 
repolarization (Hondeghem, et al., 2001), measured in this study as the difference between 
APD90 and APD30). As a measure of late repolarization, triangulation has previously been 
used as one of several metrics comprising a quantitative index of arrhythmia risk in the 
TRIaD assay, an ex vivo whole heart action potential study (Hondeghem, 2008). 
Transmembrane voltage signals obtained using VSO sensors can measure the effects of a 
drug on the complete action potential waveform (Blazeski, et al., 2012; Dempsey, et al., 
2016; Klimas, et al., 2016), although absolute values of transmembrane voltage are generally 
not accessible. While the use of VSO dyes can limit the duration of recording time possible, 
the relatively homogeneous and sensitive nature of the commercially available hSC-CMs 
studied here afford measurement of electrophysiological effects with high temporal and 
membrane potential differential resolution from relatively short duration recordings (< 20 
sec), supporting discrimination among APD30, APD60, APD90, whereas this resolution is lost 
in measurement of field potential by MEA. Instability of the action potential plateau phase 
(oscillatory EADs) are clearly resolved using VSO methods, but can be more difficult to 
detect in MEA field potential recordings. The signal quality in MEA, and apparent field 
potential amplitude, is highly dependent on the strength of contact between the cell and 
measurement electrode, which can vary from electrode to electrode within the same well, and 
as a result of compound effect. Optical measurement platforms can be used to routinely 
perform medium throughput measurements of the electrical activity of hSC-CMs as intended 
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by the CiPA initiative, and can support test article versus vehicle assessments at more chronic 
exposures.  
In a companion CiPA cross-platform study using MEA technology conducted in parallel 
to this one, recordings 2-5 minutes in duration were collected in spontaneously beating cells 
before and after a 25 minute test compound treatment, and criteria for inclusion were set to 
eliminate datasets which did not detect ≥20% increase in rate-corrected field potential 
duration FPDcF in response to IKr inhibitor E-4031 or ≥20% decrease in FPDcF in response 
to ICaL inhibitor nifedipine (Millard, et al., 2018). Eight of 18 participating sites were 
excluded from the final analysis for having failed to meet this inclusion criteria. While the 
same compounds and test concentrations were used in the CiPA VSO and MEA cross-
platform studies, a direct comparison is limited due to differences in protocol (MEA 
platforms used serum-containing media, while VSO platforms used serum-free media) and 
analysis (the MEA study chose to present FPD data as FPDcF, corrected by the empirically-
derived Fridericia formula for correcting the QT interval of the clinical electrocardiogram on 
the basis of heart rate). However, it should be noted that in this study the VSO datasets were 
overall successful in detecting IKr and ICaL inhibitor effects. All data sets in this study detected 
> 20% increase in APD90 in response to E-4031, and all spontaneously beating data sets in 
this study detected >20% APD90 decrease in response to nifedipine.  
In the present study, the reduction in APD90 was smaller in two stimulated data sets 
(Cor.4U at Q-State 11% and iCell at JHU 7%), although the spontaneously beating condition 
at Q-State decreased APD90 by 22%, suggesting that overdrive stimulation (above intrinsic 
beat rate) reduces the observed drug-induced effect. In the Q-State Cor.4U dataset, nifedipine 
stopped cardiomyocyte beating at the 3 highest test concentrations, indicating prominent ion 
channel inhibition. Interestingly, APs could not be elicited by electrical stimulation for data 
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collection in these conditions, a putative advantage of employing stimulation techniques. In 
this study, all spontaneously beating data sets detected IKr and ICaL inhibition effects with 
>20% change in APD90.  
For future studies, an even more standardized protocol can help to improve consistency 
and reproducibility among test sites. This includes plating condition, compound addition 
format, fluorescent reporter, assay solution composition, and data acquisition specifications.  
Considerations in experimental design choice, and recommendations for standardization of 
several of these assay conditions are described in Table 6. The CiPA MEA cross-platform 
study utilized serum containing media, and 10× compound addition solution (Millard, et al., 
2018). A larger CiPA study tested 28 compounds in two cell types, with ≥5 replicates and 
without electrical/optical pacing, utilizing serum-containing media at sites using MEAs and 
serum-free media by the one VSO site, and single (in 10× solution) or cumulative (in 50× 
solution) dosing (Blinova, et al., 2018). Despite the methodological variation within and 
across these studies, in general the studies demonstrate the utility of hSC-CMs in assessment 
of cardiac safety of drugs.  
Other electrophysiological parameters not encompassed by the CiPA initiative include 
calcium transient assays (alone or simultaneously with action potential) for assessing 
proarrhythmic risk liability (Bedut, et al., 2016; Pfeiffer, et al., 2016), which can also provide 
greater insight into proarrhythmia mechanisms involving calcium cycling. Optical mapping 
of wavefront propagation and conduction (Bursac & Tung, 2006; Entcheva & Bien, 2006; 
Herron, Lee, & Jalife, 2012; Lyon, et al., 2014; Pfeiffer, et al., 2014) in cell monolayers or 
tissues enable the characterization of arrhythmia events that involve conduction block and 
reentry, which are steps closer to the phenomenon of Torsade de Pointes than single cell 
arrhythmia events. Test protocols can be designed to detect forms of arrhythmia not 
examined by CiPA, including delayed after depolarizations brought about at high beat rates. 
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Mixed ion channel effects may play a role in defining proarrhythmic risk of drugs. These 
can affect repolarization to varying degrees, depending on the extent that changes in inward 
and outward channel currents offset each other. Recently, ECG recordings have shown that 
drugs that have predominantly hERG block as opposed to a balanced ion channel effect can 
be distinguished by measuring the time from J-wave to peak of the T-wave (J-Tpeak), and the 
time from peak of the T-wave to its end (Tpeak – Tend) (Johannesen, et al., 2014) in the 
ECG, a component of CiPA (Vicente, Zusterzeel, Johannesen, Mason, et al., 2018; Vicente, 
Zusterzeel, Johannesen, Ochoa-Jimenez, et al., 2018). More complete/comprehensive 
assessment of drug effects are possible with VSO approaches (but not with ECG or MEA 
recordings), in which detailed analysis of the action potential may reveal changes in multiple 
channel activity during all of its phases. Furthermore, features of the action potential may 
correspond to some extent with ECG biomarkers. For example, in transmural ECGs of the 
canine left ventricular wedge preparation, the J-wave occurs during the early notch of the 
epicardial action potential (Yan & Antzelevitch, 1996), while Tpeak occurs close to the time 
of maximum positive curvature and end of epicardial repolarization (Yan & Antzelevitch, 
1998). This additional in vitro information, coupled with ECG-based assessments relying on 
J-Tpeak, could provide greater value than either approach considered alone in discriminating 
safe vs. unsafe repolarization changes within CiPA and outside of the ionic current/in silico 
reconstructions efforts that provide a proarrhthymic risk score.  In this way, both VSO 
recordings and ECG biomarkers are useful to check for missed or unanticipated 
repolarization effects not necessarily detected on the basis of cardiac ionic current studies. 
 In summary, despite variances in protocol and acquisition method, the results of this 
study were relatively consistent across sites. The variety of methods selected here is 
representative of “real world” practice, and the consistency across sites speaks to the viability 
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of these methods. Overall, this cross-site study demonstrated that VSO technology is a useful 
in vitro tool for assessing pro-arrhythmia risk using hSC-CMs.  
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Sensor 
Kinetics 
for 
Change in 
Voltage 
Excitation 
(nm) 
Detector  
(Data 
Acquisition 
Rate 
[Hz]) 
Unit 
measur
ement 
area 
n/ 
(total 
area per 
well) 
Pacing/ 
Spontane
ous 
Cell Source 
(plating 
density) 
Imaging 
Solution 
Compound 
Addition,  
Treatment 
Duration 
Clyde 
di-4-
ANEPPS 
< 1 ms 480 
PMT  
(10,000) 
0.2 x 0.2 
mm
2
 
1 
(0.2 x 0.2 
mm
2
) 
Spont 
Cor.4U 
(78k/cm
2
); 
iCell 
(78k/cm
2
) 
Cor.4U: 
modified BMCC; 
iCell: modified 
DMEM 
Single conc. 
(5X),  
30 minutes 
JHU 
di-4-
ANEPPS 
< 1 ms 531 
CMOS 
(500) 
0.1 x 0.1 
mm
2
 
~7,000 
(10 x10 
mm
2
) 
 
Electrical 
Cor.4U 
(160k/cm
2
); 
iCell 
(255k/cm
2
); 
Modified 
Tyrode's 
Cumulative 
(10X),  
10 minutes 
Q-
State 
QuasAr < 3  ms 640 
sCMOS 
(500) 
0.4 x 0.4 
m
2
 
75,000 
(3 x 0.2 x 
0.2 mm
2
) 
Optical 
/Spont 
Cor.4U 
(70k/cm
2
); 
iCell 
(70k/cm
2
) 
Custom media 
Cumulative 
(10X),  
10 minutes 
Vala FluoVolt < 1 ms 488 
sCMOS 
(30) 
0.325 x 
0.325 
m
2
 
~3 million  
(0.58 x 
0.58 mm
2
) 
Spont 
Cor.4U 
(140k/cm
2
); 
iCell 
(78k/cm
2
) 
Modified 
Tyrode's 
Single conc. 
(1X),  
20 minutes 
 
Table 1. Summary of data acquisition and cell conditions used across each VSO site. 
Voltage-sensitive optical sensor acquisition methods were unique per site. Unit measurement 
area is the area from which single measurements were taken and parameters calculated. n is 
the typical number of measurements made per well or monolayer. Each imaging solution is 
serum-free with unique composition, as described in Supplemental Table 1. Compound 
addition denotes the intermediate concentration (conc.) of compound added to the cells (e.g. 
1×, 5×, 10× the test concentration). Refer to Methods for more details.  
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Compound Currents Inhibited Conc. 1 (µM) Conc. 2 (µM) Conc. 3 (µM) Conc. 4 (µM) 
E-4031 IKr 0.003 0.01 0.03 0.1 
Nifedipine ICa 0.01 0.03 0.1 0.3 
Mexiletine INa 1 3 10 30 
JNJ 303 IKs 0.01 0.03 0.1 0.3 
Flecainide Multiple (IKr , INa , Ito) 0.1 0.3 1 3 
Moxifloxacin IKr , ICa 3 10 30 100 
Quinidine Multiple (IKr , ICa , INa , If) 0.3 1 3 10 
Ranolazine Multiple (IKr , INaL) 1 3 10 30 
 
 Table 2. Test compounds and dosages.  
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  Clyde  JHU QState Vala (*) 
Cor.4U (n=192) iCell  (n=192) Cor.4U (n=9) iCell (n=9) Cor.4U (n=59) iCell (n=57) Cor.4U (n=33) iCell (n=36) 
mean 
(SD) CoV 
mean 
(SD) CoV 
mean 
(SD) CoV 
mean 
(SD) CoV 
mean 
(SD) CoV 
mean 
(SD) CoV 
mean 
(SD) CoV 
mean 
(SD) CoV 
Spont 
CL (s) 
0.81 
(0.11) 0.14 
1.3 
(0.3) 0.23         
1.7 
(1.1) 0.65 
1.7 
(0.3) 0.18 
1.3 
(0.2) 0.15 
3.7 
(0.4) 0.11 
APD30 
(ms) 
127.2 
(21.8) 0.17 
259 
(46.2) 0.18         
213.3 
(63.6) 0.30 
301.4 
(61.7) 0.20 
255.8 
(32.7) 0.13 
466.5 
(83.1) 0.18 
APD60 
(ms) 
172 
(19.6) 0.11 
403.7 
(63.5) 0.16         
294.6 
(91.6) 0.31 
442.4 
(66.5) 0.15 
333.9 
(32) 0.10 
726 
(59.8) 0.08 
APD90 
(ms) 
215.4 
(26) 0.12 
471.7 
(59.9) 0.13         
413.5 
(102) 0.25 
563 
(61.2) 0.11 
404.1 
(32.7) 0.08 
807 
(58.7) 0.07 
TRise 
(ms) 
9.9  
(3) 0.30 
5.9 
(1.5) 0.25         
25.7 
(10.3) 0.40 
13.7 
(1.9) 0.14 
36.1 
(3.3) 0.09 
41.6 
(5.6) 0.13 
Triang 
(ms) 
88.3 
(22.4) 0.25 
212.7 
(57.9) 0.27         
198.6 
(59.3) 0.30 
261.6 
(26.9) 0.10 
148.3 
(7.7) 0.05 
340.5 
(57.3) 0.17 
1Hz 
CL (s)         1   1   1   1           
APD30 
(ms)         
265.2 
(12.8) 0.05 
271.4 
(17.7) 0.07 
198.2 
(49.6) 0.25 
257.1 
(43.3) 0.17         
APD60 
(ms)         
349.1 
(13.8) 0.04 
380.1 
(16.7) 0.04 
274.5 
(72.1) 0.26 
372.8 
(41.3) 0.11         
APD90 
(ms)         
442.4 
(16.1) 0.04 
524.3 
(24.3) 0.05 
378.6 
(80.9) 0.21 
497.8 
(36.6) 0.07         
TRise 
(ms)         
16.3  
(2) 0.12 
21.3 
(2.5) 0.12 
26  
(9.6) 0.37 
16.1 
(7.8) 0.48         
Triang 
(ms)         
177.3 
(12.9) 0.07 
252.3 
(22.9) 0.09 
180.4 
(46.8) 0.26 
240.7 
(25.7) 0.11         
 
Table 3. Measured baseline action potential parameters. Average (mean), standard 
deviation (SD) and coefficient of variation (CoV) of action potential parameters recorded 
under baseline (not test article treated) conditions. *In the presence of DMSO.  
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All Sites, All Data Linear Regression r2 
Cor.4U Y = 0.09718*X + 197.4 0.2468 
iCell Y = 0.1286*X + 324.8 0.8117 
  
Table 4. Dependence of APD90 on cycle length. Linear regression for all sites, all 
spontaneous or stimulated baseline data combined. X: cycle length (ms); Y: APD90 (ms). 
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Drug µM 
Clyde JHU Q-State Vala 
(n=3) (n=1) (n=3) (n=3 ) 
Cor.4U iCell Cor.4U iCell Cor.4U iCell Cor.4U iCell 
Spont Spont 1 Hz 1 Hz Spont 1 Hz Spont 1 Hz Spont Spont 
E-4031 
0.003 
          
0.01 
          
0.03 
B(2) A(2) 
    
C (1) 
  
A (2) 
T(1) B(1) 
0.1 T (3) T (3) B (1) 
 
Q (3) Q (3) C (2) 
 
A (3) A (2) 
Nifedipine 
0.01 
          
0.03 
    
Q (3) Q (3) 
    
0.1 
    
Q (3) Q (3) Q (2) 
  
T (3) 
0.3 
  
Q (1) 
 
Q (3) Q (3) Q (3) 
  
T (3) 
Mexiletine 
1 
          
3 
          
10 
      
Q (2) 
   
30 
 
Q (3) 
    
Q (3) 
  
IrrBeat 
(3) 
JNJ 303 
0.01 
          
0.03 
          
0.1 
          
0.3 
          
Flecainide 
0.1 
          
0.3 
          
1 
 
A (3) 
    
Q (1) 
   
3 B (3) 
C(2) 
    
Q (2) C (2) 
 
A (2) 
Q(1) 
Moxifloxacin 
3 
          
10 
          
30 
          
100 
          
Quinidine 
0.3 
          
1 
         
A (3) 
3 
 
T (3) 
    
A (2) 
  
A (2) 
10 
 
Q (3) Q (1) Q (1) Q (3) Q (2) T (3) 
  
A (3) 
Ranolazine 
1 
          
3 
          
10 
        
A (2) 
 
30 
        
B,C (3) A (1) 
 
Table 5. Incidence of arrhythmia-like events. Events are annotated by number and type, 
which consist of single transient depolarizations during the plateau phase of the AP (type A), 
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oscillating or multiple depolarizing events during the plateau phase (type B), rapid 
depolarizing events during the late repolarization phase of the AP (type C), tachycardia- like 
with sustained high frequency spontaneous activity > 2Hz (type T), quiescent cells having no 
recorded AP signal for a period of the recording time (> 20s) (type Q), and irregular beat 
rhythmicity (extended period between two beats) (type IrrBeat). AP waveforms for different 
types of events are shown in Supplemental Figure 1. 
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Assay Condition Variations (Recommendation) Considerations 
Cell  type iCell  hSC-CM 
Cor.4U hSC-CM 
Cell-type specific protocols and 
criteria for data interpretation 
should be util ized. 
Cell  culture duration 4 to 17 days Cells should be maintained in 
culture for a sufficient time 
following thawing or dissociation 
to reduce variation in baseline 
characteristics. 
Cell  culture modifications  Dissociation, viral transfection Minimization of cell  handling 
steps and implementation of 
quality inclusion criteria for 
baseline variation may decrease 
variability in experimental results. 
Beat rate control  Electrically or optically stimulated 
at 1 Hz, or (spontaneously 
beating) 
Beat rate control is meant to 
avoid rate-duration dependence, 
but rate constraint can suppress 
drug-induced effects and is 
technically l imiting. 
Test article addition Cummulative or (single) dosing, 
(full) or 1:10 to 1:2 media 
exchange 
Addition of 5X-10X intermediate 
stock solution and cumulative 
dosing has greater tendency to 
stop spontaneous beating. 
Test article exposure duration 10, (20, 30 minutes) Shorter exposure accomodates 
repeat-dosing and increases 
throughput, but may limit 
sensitivity and be susceptible to 
non-equilibrium conditions 
Recording rate 30 to 10,000 Hz Higher recording rate supports 
finer time scale resolution. 
 ≥ 30 Hz for CL, APD 
 ≥ 500 Hz for Trise 
Imaging solution Various ionic and supplemental 
formulations 
The constituency of assay solution 
and ionic composition have 
complex influences on cell  
electrophysiological properties , 
potentially affecting cycle length 
and action potential duration. 
These may be best examined 
through single factor variation. 
Table 6. Recommended assay conditions. Evaluation of select assay condition variants 
occurring in this study and recommendations for routine use. 
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Figure 1. Baseline optical signals from voltage sensing optical sensors (VSOs). Baseline 
action potential signals from Cor.4U and iCell cardiomyocytes recorded using VSOs 
recorded at four sites (Clyde, JHU, Q-State, and Vala). Signals are shown as point/line plots 
with points indicating sample rate of acquisition device.  
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Figure 2.  Relationship of APD90 to cycle length. APD90 (ms) and cycle length (ms) data in 
control spontaneously beating or 1Hz stimulated . (A) Cor.4U and (B) iCell cardiomyocytes. 
Data are fit by linear regression. 
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Figure 3.  The effect of vehicle (DMSO) on optical action potential parameters. (A) 
Example AP signals from Cor.4U and iCell cardiomyocytes prior to (black) and after 30 min 
exposure to DMSO (blue line) as measured at one site Clyde Biosciences (CB). (B) The 
relative change in electrophysiological parameters across 8 plates of 96 well format measured 
at CB from spontaneously active cells. The values in each plate are an average of 
measurements from 10 wells, the boxes denote the 25% and 75% limits and the whiskers 9% 
and 91% limits. (C) The changes in APD90 due to addition of vehicle across all sites recorded 
from both stimulated and spontaneously active cells. The line represents median value, the 
box 25% to 75% limits and the whisker 9% to 91%. Note that the Vala site did not record a 
baseline value and only recorded in the presence of DMSO. 
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Figure 4.  Electrophysiological responses to a subset of drugs from one site (CB). 
Response of Cor.4U and iCell cardiomyocytes to (A) E-4031, (B) nifedipine, (C) mexiletine, 
and (D) JNJ303. (Left) Sample records of changes in AP characteristics in response to (A) 30 
nM E-4031, (B) 300 nM nifedipine, (C) 30 M mexiletine, and (D) 10 M JNJ 303. (Right) 
Changes in cycle length, APD90, triangulation (APD90-APD30) and Trise (10 to 90% of 
upstroke) with addition of drug. Red boxes indicate the test concentrations of drug used in the 
records on the left. 
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Figure 5.  Change in ADP90 in response to a subset of drugs from all four test sites. Plots 
of the mean and standard error of the relative change in APD90 from vehicle control (DMSO) 
(ΔΔAPD90) for the 4 sites, for (A) Cor.4U, and (B) iCell cardiomyocytes, under 
spontaneously beating (spont) or electrically or optically paced (1Hz) conditions. Q indicates 
a quiescent response (cells stopped beating), Ar denotes an arrhythmia event as detailed in 
Table 5). 
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SUPPLEMENTAL TABLES & FIGURES  
 Extracellular 
Matrix Protein 
Days of culture 
(day dissociated) 
Imaging 
Media 
Imaging Solution Ionic 
Composition 
Imaging Solution 
Supplement 
pH 
Clyde 
(Cor.4U) 
fibronectin (10 
µg/ml) 
Cor.4U: 4-8 
 
BMCC 86.3 NaCl 
4.4 KCl 
1.5 CaCl2 
0.81 MgSO4 
0.91 NaH2PO4 
25 glucose 
7.5x10-4 KNO3 
3.8x10-5 Na2SeO3*5H20 
34 NaHCO3 
7.4 
Clyde 
(iCell) 
fibronectin (10 
µg/ml) 
iCell: 10-15 DMEM 110 NaCl 
5.33 KCl 
1.8 CaCl2 
0.81 MgSO4 
0.91 NaH2PO4 
10 galactose 
10 Na-pyruvate 
2.5x10-4 Fe(NO3)3 
44 NaHCO3 
7.4 
JHU Geltrex (1:100 
dilution) 
Cor.4U: 10 (2) 
iCell: 10 
Tyrode's 135 NaCl 
5.4 KCl 
1.8 CaCl2 
1.0 MgCl2 
0.33 NaH2PO4 
5 glucose 
5 HEPES 
Cor.4U: 0.01 
blebbistatin 
7.4 
Q-State 0.1% gelatin, 10 
µg/mL 
fibronectin in 
0.1% gelatin  
Cor.4U: 7-10  
iCell:14-17 
(transduced at 3-
5, dissociated at 
6) 
Custom 129 NaCl 
5.3 KCl 
1.8 CaCl2 
0.81 MgSO4 
0.91 NaH2PO4 
10 D-(+)-galactose 
1 Na-pyruvate 
2.5x10-4 Fe(NO3)3 
44 NaHCO3 
7.3 
Vala Cor.4U: 
fibronectin (10 
µg/mL) 
iCell: Matrigel 
(250 µg/ml) 
Cor.4U: 6 
iCell:10 
Tyrode's 135 NaCl 
4.5 KCl 
2.0 CaCl2 
1.0 MgCl2 
10 glucose 
25 HEPES 
7.4 
 
Supplemental Table 1. Composition of experimental solutions. Each site used the cell 
manufacturer-supplied plating and maintenance medias. Days of culture post-thaw are 
recorded, some sites dissociated and re-plated the cells during this period. All imaging 
solutions were serum free, composition is described in mM.  
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Clyde (Spontaneous) Q-State (Spontaneous) Vala (Spontaneous) 
mean SD mean SD mean SD 
Cor.4U 
Intercept 
(ms) 
128 12 373 24 265 27 
Slope 0.108 0.015 0.024 0.012 0.108 0.020 
r
2
 0.2201 0.06954 0.476 
iCell 
Intercept 
(ms) 
289 12 356 37 500 81 
Slope 0.138 0.009 0.125 0.022 0.083 0.022 
r
2
 0.570 0.375 0.302 
 
Supplemental Table 2. Linear regression of individual sites APD90 by cycle length (as 
relates to Figure 2). 
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Drug Indication 
FDA 
Approval 
Credible 
Meds: Risk 
of TdP 
ETPCfree  
Range 
[µM] 
ETPCfree 
References 
Cmax of 
Clinical QTc 
Prolongation 
>10 ms [µM] 
Clinical References Concentrations 
Tested [µM] 
(First arrhythmia) QTc 
Arrhy
thmia 
E-4031 
experimental 
antiarrhythmic 
(class III) 
- - 
0.001 – 
0.021 
(14,15,30) 0.003 (15)  
0.003 – 0.1  
(0.03 µM EAD) 
Nifedipine 
antihypertensive 
(calcium channel 
block) 
1989 
No 
evidence of 
risk 
0.002 – 
0.01 
(22,33,40)    
0.01 – 0.3  
(0.03 µM Q, 
Tachy) 
Mexiletine 
antiarrhythmic 
(class IB) 
1998 
No 
evidence of 
risk 
0.47 – 
1.1 
(19,40)    
1 – 30  
(10 µM Q and 
Irregular Beats) 
JNJ 303 
development 
compound, JNJ-
38445303 
IKs blocker 
- - 
Not 
tested 
clinically 
(39)    
0.01 – 0.3  
(none) 
Flecainide 
antiarryhthmic 
(class Ic) 
1985 Known Risk 0.3 – 1.9 (10,25,32) 0.59 – 0.72 (2,12) (1,9) 
0.1 – 3  
(1 µM EAD, Q) 
Moxifloxacin antibiotic 1999 Known Risk 0.2 – 4.8 (4,5,26,37) 2.1 – 4.1 
(13,16,28
,35) 
 
3 – 100  
(none) 
Quinidine 
antiarrhythmic 
(class Ia) 
1950 Known Risk 0.29 – 22 (6,25,29,32) 0.064 – 2.3 
(6,27,29,
32,36) 
(9) 
0.3 – 10  
(1 µM EAD, Q) 
Ranolazine antianginal 2006 
Conditional 
Risk 
0.62 – 
5.2 
(8,16,21,38) 3.5 – 9.1 (16,21)  
1 – 30  
(10 µM EAD) 
 
Supplemental Table 3. Description and clinical usage of drugs tested.  Clinical status and 
CredibleMeds® categorization of TdP risk (QTDrugsList at https://crediblemeds.org). 
Unbound effective therapeutic plasma concentration (ETPCfree) and plasma concentrations 
(unbound Cmax) associated with QTc prolongation of the drugs tested in this study, coincide 
with the lower concentrations tested. The lowest test concentrations at which arrhythmia 
occurred are provided for comparison. 
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Compound 
hERG 
(IKr) IC50 
[µM] 
hERG 
reference 
Nav1.5 
(INa) IC50 
[µM] 
Nav1.5 
reference 
Cav1.2 
(ICaL) IC50 
[µM] 
Cav1.2 
reference 
IKs 
IC50 
[µM] 
IKs 
reference 
Nav1.5-
Late (INaL) 
IC50 [µM] 
Nav1.5-
Late 
reference 
E-4031 
0.005 - 
0.4 
(30)         
Nifedipine 44 - 275 (23,30) 88 (23) 0.012 (23)     
Mexiletine 3.7-28.9 (18,24) 8.4 - 135 (7,11,20) 38.2 (24)   9 (24) 
JNJ 303 12.6 (39) 3.3 (39)   0.064 (39)   
Flecainide 
0.004 – 
3.9 
(7,23,30,3
2) 
6.2 – 10.7 
(7,11,20,2
3) 
27, >20 (7,23) 
  
  
Moxifloxacin 77 – 93 (7,17,23) 
1112, 
>350 
(7,23) 173, >350 (7,23)     
Quinidine 0.3 – 1.5 
(7,11,23,2
4,30) 
12 – 46 
(7,11,23,2
4) 
6.4- 51.6, 
>5.4 
(7,23,24) 
  
9.4 (24) 
Ranolazine 
8.3 – 
106 
(24,31,34) 1.4  – 10 (3,7,24) 296 (3) 
  
7.9 (24) 
 
Supplemental Table 4. Cardiac ion channel inhibition by test compounds. 
. 
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Supplemental Figure 1. Classification of “cellular arrhythmias.” Exemplar records 
recorded from hSC-CM with distinct characteristics. Type A events are single transient 
depolarizations during the plateau phase of the AP. Type B events are oscillating or multiple 
depolarizing events during the plateau phase. Type C events are rapid depolarizing events 
during the late repolarization phase of the AP. Tachycardia- like events (Type T) are sustained 
high frequency spontaneous activity (>2Hz), and quiescent cells have no recorded AP signal 
for a period of the recording time (> 20s) (Type Q) . 
  
2 s
Quiescence	(Type	Q)
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G Triang/APD90 
  
 
Supplemental Figure 2. Change in action potential parameters in response to all drugs 
from all four test sites. Plots of the mean and standard error of the relative change from 
vehicle control of: (A) (Spontaneous) Cycle length (CL), (B) APD30, (C) APD60, (D) APD90, 
(E) Rise time (Trise), (F) Triangulation (Triang), and (G) Normalized triangulation 
(Triang/APD90). (Left column) Cor.4U and (right column) iCell cardiomyocytes, under 
spontaneously beating (spont) or electrically or electrically/optically paced (1Hz) conditions. 
Q, Ar denote events described in Table 5. 
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